Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children

Journal of Infectious Diseases

Volumn 190, Issue 12, 2004, Pages 2096-2103

  Belshe, Robert B ^a,l   Newman, Frances K ^a   Anderson, Edwin L ^a,k   Wright, Peter F ^b   Karron, Ruth A ^c   Tollefson, Sharon ^b   Henderson, Frederick W ^f   Meissner, H Cody ^e   Madhi, Shabir ^h   Roberton, Don ⁱ   Marshall, Helen ⁱ   Loh, Richard ^m   Sly, Peter ^j   Murphy, Brian ^d   Tatem, Joanne M ^g   Randolph, Valerie ^g   Hackell, Jill ^g   Gruber, William ^j   Tsai, Theodore F ^g  

^a SAINT LOUIS UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e TUFTS MEDICAL CENTER   (United States)

^f UNIVERSITY OF NORTH CAROLINA   (United States)

^g WYETH RESEARCH   (United States)

^h UNIVERSITY OF THE WITWATERSRAND   (South Africa)

ⁱ UNIVERSITY OF ADELAIDE   (Australia)

^j New Children's Hospital   (Australia)

^k UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^l SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

LIVE VACCINE; PARAINFLUENZA VACCINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE;

ANTIBODY RESPONSE; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HUMAN; IMMUNOGENICITY; INFANT; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PARAINFLUENZA VIRUS 3; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RNA VIRUS INFECTION; VIRUS INFECTION; VIRUS REPLICATION; VIRUS SHEDDING;

ADMINISTRATION, INTRANASAL; ANTIBODIES, VIRAL; DOUBLE-BLIND METHOD; HUMANS; INFANT; PARAINFLUENZA VACCINES; PARAINFLUENZA VIRUS 3, HUMAN; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIROVIRUS INFECTIONS; VACCINES, COMBINED; VIRUS SHEDDING;

EID: 10444255610     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/425981     Document Type: Article

References (30)

1. La Via WV, Marks MI, Stutman HR. Respiratory syncytial virus puzzle: clinical features, pathophysiology, treatment, and prevention. J Pediatr 1992; 121:503-10.
2. Anderson LJ, Hendry RM, Pierik LT, Tsou C, McIntosh K. Respiratory syncytial virus infections, reinfections and immunity: a prospective, longitudinal study in young children. New Engl J Med 1979; 300:530-4.
3. Glezen WP, Denny FW. Epidemiology of acute lower respiratory disease in children. N Engl J Med 1973; 288:498-505.
4. Brandt CD, Kim HW, Arrobio JO, et al. Epidemiology of respiratory syncytial virus infection in Washington, D.C. III. Compositive analysis of eleven consecutive yearly epidemics. Am J Epidemiol 1973; 98:355-64.
5. Belshe RB, VanVoris LP, Mufson MA, Hyler L. Epidemiology of severe respiratory syncytial virus infections in Huntington, West Virginia. WV Med J 1981; 77:49-52.
6. Monto AS, Sullivan KM. Acute respiratory illness in the community: frequency of illness and the agents involved. Epidemiol Infect 1993; 110:145-60.
7. Denny FW, Clyde WAJ. Acute lower respiratory tract infections in nonhospitalized children. J Pediatr 1986; 108:635-46.
8. Gruber WC. Bronchiolitis: epidemiology, treatment, and prevention. Semin Pediatr Infect Dis 1995; 6:128-34.
9. Henderson FW, Collier AM, Clyde WA, Denny FW. Respiratory syncytial virus infections, reinfections and immunity: a prospective, longitudinal study in young children. N Engl J Med 1979; 300:530-4.
10. Parrott RG, Vargoski A, Luckey A, et al. Clinical features of infection with hemadsorption viruses. N Engl J Med 1959; 260:731-8.
11. Glezen WP, Frank AL, Taber LH, et al. Parainfluenza virus type 3: seasonality and risk of infection and reinfection in young children. J Infect Dis 1984; 150:851-7.
12. Institute of Medicine. New vaccine development: establishing priorities. Vol 1. Diseases of importance in the United States. Washington DC: National Academy Press, 1988.
13. Belshe RB, Mendelman, PM, Treanor J, et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med 1998; 338:1405-12.
14. Belshe RB, Newman F, Tsai T, et al. Phase II evaluation of parainfluenza type 3 cold passage mutant 45 live attenuated vaccine in healthy children 6-18 months old. J Infect Dis 2004; 189:462-70.
15. Karron RA, Belshe RB, Wright PF, et al. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants. Pediatr Infect Dis J 2003; 22:394-405.
16. Wright PF, Karron RA, Belshe RB, et al. Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J Infect Dis 2000; 182:1331-42.
17. Karron RA, Wright PF, Newman FK, et al. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in healthy infants and children. J Infect Dis 1995; 172:1445-50.
18. Coates HV, Alling DW, Chanock RM. An antigenic analysis of respiratory syncytial virus isolates by a plaque reduction neutralization test. Am J Epidemiol 1966; 83:299-313.
19. Clements ML, Belshe RB, King J, et al. Evaluation of bovine, cold-adapted human, and wild-type human parainfluenza type 3 viruses in adult volunteers and in chimpanzees. J Clin Microbiol 1991; 29:1175-82.
20. Belshe RB, Karron RA, Newman FK, et al. Evaluation of a live attenuated, cold-adapted parainfluenza virus type 3 vaccine in children. J Clin Microbiol 1992; 30:2064-70.
21. Boyce TG, Gruber WC, Coleman-Dockery SD, et al. Mucosal immune response to trivalent live attenuated intranasal influenza vaccine in children. Vaccine 1999; 18:82-8.
22. Snyder MH, Banks S, Murphy BR. Determination of antibody response to influenza virus surface glycoproteins by kinetic enzyme-linked immunosorbent assay. J Clin Microbiol 1988; 26:2034-40.
23. Randolph VB, Kandis M, Stemler-Higgins P, et al. Attenuated temperature-sensitive respiratory syncytial virus mutants generated by cold adaptation. Virus Res 1994; 33:241-59.
24. Hall SL, Stokes A, Tierney EL, et al. Cold passaged human parainfluenza 3 virus contain ts and non-ts mutations leading to attenuation in rhesus monkeys. Virus Res 1992; 22:173-84.
25. van Wyke Coelingh KL, Winter C, Murphy BR. Antigenic variation in the hemagglutinin-neuraminidase protein of human parainfluenza type 3 virus. Virology 1985; 143:569-82.
26. van Wyke Coelingh KL, Winter CC, Tierney EL, et al. Antibody responses of humans and nonhuman primates to individual antigenic sites of the hemagglutinin-neuraminidase and fusion glycoproteins after primary infection or reinfection with parainfluenza type 3 virus. J Virol 1990; 64:3833-43.
27. Waner JL. Mixed viral infections: detection and management. Clin Microbiol Rev 1994; 7:143-51.
28. Kehl SC, Henrickson KJ, Hua WM, Fan J. Evaluation of the Hexaplex assay for detection of respiratory viruses in children. J Clin Microbiol 2001; 39:1696-1701.
29. Drews AL, Atmar RL, Glezen WP, Baxter BD, Piedra PA, Greenberg SB. Dual respiratory virus infections. Clin Infect Dis 1997; 25:1421-9.
30. Henrickson KJ. Parainfluenza viruses. Clin Microbiol Rev 2003; 16: 242-64.